Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab +/- Bevacizumab in Follicular NHL
NCT00193492Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2005
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in follicular lymphoma (FL) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Sep 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00193492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193492.